
ConcertAI Announce Strategic Agreement with Bayer to Accelerate Clinical Development in Precision Oncology
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ConcertAI announced a multi-year agreement with Bayer to leverage ConcertAI's Translational360™ -- powered by Guardant Health liquid biopsy genomic data -- and AI SaaS solutions, which use artificial intelligence and machine learning (AI/ML)-derived insights to accelerate clinical development in precision oncology.
The agreement will fully leverage ConcertAI's newly launched Translational360™, an integrated research-grade longitudinal clinical molecular database that taps into the CancerLinQ network of de-identified cancer patient data from over 9 million records coming from all 50 states in the U.S.
Translational360™ combines clinical, genomic, transcriptomic, and whole-slide imaging (WSI) from comprehensive molecular testing for deep phenotypical and genomic insights. Transcriptomics is increasingly a foundation of biopharma translational sciences, allowing researchers to understand disease molecular mechanisms, basis of patient response, and inter-patient variability that's essential for developing new therapeutics. Too often, clinical trial results in early phases are ambiguous with idiosyncratic positive and negative responses. The integrated data solutions and advanced AI enable selection of programs with the highest likelihood of success and design trials informed by multi-modal, multi-genomic, and transcriptomic data and AI.
'This partnership furthers causal biological inferences, where multi-modal and multi-molecular data can be integrated with AI/ML-based approaches across discovery, translation, and development, accelerating oncology pipelines, allowing our biopharma partners to deliver better medicines faster," said Jeff Elton, Ph.D., CEO of ConcertAI. 'This partnership builds on a multi-year history of working together and is unique in offering both tissue and liquid biopsy molecular data, allowing insights into patterns of treatment response, acquisition of resistance, AI modeling of likely success and benefit, informing program priority and clinical study design.'
'Data play a critical role in providing a multi-dimensional understanding of a tumor, the clinical environment, and the patient's response to therapy,' said Helmy Eltoukhy, Chairman and co-CEO of Guardant Health. 'The real-world data can provide access to unprecedented insights into a patient's cancer journey, including a tumor's complex systemic interactions, to help users navigate critical decision points as they develop novel targeted therapies.'
'As cancer rates continue to rise, we're committed to advancing next-generation solutions that can speed up drug discovery and clinical development, enabling us to bring precision oncology treatments to patients faster,' said Sai Jasti, Head of Data Science and AI for Pharma R&D at Bayer. 'By combining ConcertAI's powerful data solutions with Bayer's scientific and AI expertise, we aim to enhance the use of real-world data and cutting-edge AI to boost R&D productivity and ultimately deliver transformative precision therapies to those who need them.'
"More AI-designed new molecular entities are progressing faster in first-in-human trials, which is a great milestone,' said Claudio D'Ambrosio, Ph.D., Chief Revenue Officer of ConcertAI. 'Our entire R&D process has been historically built on studying controlled cell lines and animal models that don't reflect the interspecies differences, the physiology, and the different biological barriers we have in humans. We are flipping this paradigm on its head. We need to start with human cancer genomes and phenotypes and 'reverse translate.' Unlike only a few years ago, we now have powerful human data.'
About ConcertAI:
ConcertAI is a leader in predictive and generative AI SaaS and multi-modal real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai ™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon ® provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ ® is an initiative of ConcertAI, empowering oncology providers with ASCO-aligned automated QOPI and ASCO Certified ® quality solutions and SmartLinQ™ analytic services. Headquartered in Cambridge, MA, ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at concertai.com.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
How to Organize a Health Technology Business with Focus on 10+ Organizational Archetypes
Discover the evolving organizational structures of digital health businesses in the Pharma and MedTech sectors. This report analyzes 11 HealthTech archetypes over 15 years, offering insights on performance across key KPIs, future trends, and strategic recommendations. Featured companies include Bayer, Roche, and more. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "How to Organize a HealthTech Business?" report has been added to offering. This report sheds light on how to organize digital health businesses, especially at large Pharma and MedTech companies. By looking at how other companies have been managing their HealthTech businesses over the last 15 years, 11 different HealthTech organizational archetypes are being detailed out in the report, including their objectives, responsibilities, team sizes, target partner company stages, governance, value propositions for their partners, business impact evaluations across 4 KPIs and real-life examples from companies who had deployed these structures. Performance of the 11 archetypes are then evaluated and compared across the four main KPIs which are based on finding partners, launching solutions, driving usages & cultural change support. Based on the evaluation of the success and impact of these archetypes, the report presents a benchmarking table of HealthTech business organizations today. With a deep-dive into the evolving trends in HealthTech business organizations responding to the changing market conditions across three main market phases, 5 trend points for future and relevant recommendations are provided on what needs to be done to stay competitive and move forward in growing digital health market. Questions the report answers: What are the archetypes to organize HealthTech businesses at Pharma and MedTech companies? What are the different objectives and responsibilities of each organizational archetype? How are the archetypes governed at larger corporates? How does each organizational archetype perform? Which Pharma and MedTech apply which archetype to manage their HealthTech business today? How did the archetypes evolve to adept the market conditions today? What does the market require for organization of HealthTech businesses in 3-5 years? Interested parties can benefit from this report in the following ways: Consultants: gain insights into different organizational structures within the HealthTech industry, and enhance the ability to advise clients on optimal structuring and strategic alignment for digital health initiatives Strategy heads: understand how leading organizations structure their HealthTech initiatives, which can inform strategic planning and decision-making processes Business unit heads: understand how to integrate digital health solutions into the units effectively, determine the most suitable structure for the unit, and align with overall corporate objectives Digital health unit heads: benchmark your organizational structure against others, know what is needed in terms organizational structure to stay competitive in the growing digital health market, and optimize your organizational structure to foster innovation and integration with business units In this report, the following companies are mentioned: Bayer Roche Biogen Sanofi Siemens Healtineers GE Healthcare Janssen (J&J) MSD Merck KGaA Novartis Becton Dickenson and Company *30 min report consultation with a research analyst available with the purchase of an enterprise license Key Topics Covered: Archetype-1: Central Teams Archetype-2: De-Central Teams Archetype-3: Carve-Outs Archetype-4: Innovation Hubs Archetype-5: Incubators Archetype-6: Accelerators Archetype-7: Collaborative Accelerators Archetype-8: People Accelerators Archetype-9: Marketplace Organizations Archetype-10: Venture Funds Archetype-11: Outsourcing The Influence of Market Maturity on the Development of HealthTech Organizational Forms Building Successful HealthTech Teams for the Next 3-5 Years For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Fungi concerns spark nationwide recall of Zicam® and Orajel™ products
(WJW) – According to the U.S. Food and Drug Administration, Church & Dwight Co., Inc. is voluntarily recalling some Zicam® and Orajel™ products because fungi could be present in the items' cotton swab components. The recalled products include all lots within expiry of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs to the consumer level. Consumers are advised to 'immediately' stop using the recalled products. Major grocery chain slashing prices for the summer 'Swabs found to contain microbial contamination can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries,' reads the recall alert. 'The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions.' The FDA said, so far, no serious adverse events associated with the affected product have been reported. The recalled products were distributed nationwide in the United States and in Puerto Rico, said the FDA. Brain-eating amoeba: How are people infected? Here's the specific details to check for: Zicam® Cold Remedy Nasal Swabs, with UPC 732216301205, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam® Nasal AllClear Swabs, with UPC 732216301656, all lots: A nasal cleansing swab product (discontinued in December 2024). Orajel™ Baby Teething Swabs, with UPC 310310400002, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. You can view images of the recalled products in the slideshow below: 'This recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by this recall,' states the FDA on its website. Consumers can CLICK HERE or call (800) 981-4710 for refund details. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Compliance Scorecard Releases Major Platform Upgrade with Enhanced Security Awareness Training, Risk Intelligence, and Compliance Automation
Company to Showcase Latest Innovations at Pax8 Beyond 2025 DOVER, N.H., June 09, 2025--(BUSINESS WIRE)--Compliance Scorecard™, a Compliance as a Service (CaaS) platform provider, today announced significant new features that redefine how MSPs deliver Compliance-as-a-Service (CaaS) – with real-time metrics, streamlined audit readiness and customizable client governance capabilities. "Our latest release reflects what MSPs have been asking for – less noise, more context, and real metrics that map directly to frameworks like CMMC, HIPAA, FTC Safeguards and SOC 2," said Tim Golden, Founder and CEO of Compliance Scorecard. "It's not just a checklist anymore. We're helping MSPs prove compliance with confidence." Security Awareness Training is no longer a checkbox. Frameworks including CIS Control 14 demand governance, metrics, and measurable outcomes. Compliance Scorecard is the first platform to give MSPs live SAT metrics that are tied to compliance frameworks and fully auditable. Compliance Scorecard's KPI engine allows MSPs and their clients to define custom success metrics including phishing click rate, quiz scores, or training frequency, and see progress over time. Key New Features: Security Awareness Training (SAT) Scorecard: Unified SAT dashboard and KPI tracking across Symbol Security, Huntress, CyberHoot, Phin and others. Metrics tie directly to client policies, SOPs, and user adoption, with CIS Control 14 addressed through policy-backed, real-time insights. Risk and Assessment Automation: Built-in RACI modeling (Responsible, Accountable, Consulted, Informed) for assessment events, audit-aligned evidence fields (Examine, Interview, Test), and seamless connections between control objectives and the Risk Register. Policy and Adoption Engine: Unified policy templates for MSPs and clients, exportable adoption metrics, and customizable client email workflows for user invites, policy approvals and campaign tracking. Enhanced Platform Experience: Role-based access control with collapsible dashboards with persistent settings, and a mobile-optimized Trust Center and Knowledge Base for intuitive filtering and sorting. Compliance Scorecard will showcase the new release at Pax8 Beyond 2025, offering live demos, strategy sessions, and one-on-one consultations with its compliance experts. To learn more, visit or explore the offering in the Pax8 Marketplace. About Compliance Scorecard™ Compliance Scorecard is a leader in governance, risk, and compliance solutions for Managed Service Providers (MSPs). Built with a security-by-design philosophy, the platform simplifies compliance management, empowering MSPs to grow their business while protecting clients. With features such as policy management, risk registers, asset management, and SharePoint integration, Compliance Scorecard helps MSPs manage multiple clients and scale their compliance services with ease. Follow Compliance Scorecard on YouTube, LinkedIn and Facebook. View source version on Contacts Media: Kim PegnatoLongview Strategies781-835-7118Kpegnato@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data